The combined therapy myo-inositol plus D-chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients

European Review for Medical and Pharmacological Sciences

Volumn 17, Issue 4, 2013, Pages 537-540

  Minozzi, M ^a   Nordio, M ^a   Pajalich, R ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Ars Medica Hospital   (Italy)

Author keywords

Biological variation; LDL; Lipids; Polycystic ovary syndrome

Indexed keywords

CHOLESTEROL; DEXTRO CHIRO INOSITOL PLUS MYOINOSITOL; HIGH DENSITY LIPOPROTEIN; INOFOLIC COMBI; INOSITOL DERIVATIVE; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD PRESSURE; BODY FAT; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG FORMULATION; DYSLIPIDEMIA; FEMALE; GLUCOSE METABOLISM; HOMEOSTASIS; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; LONGITUDINAL STUDY; METABOLIC PARAMETERS; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; RISK REDUCTION; TREATMENT DURATION; TREATMENT OUTCOME; WAIST HIP RATIO;

ADULT; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INOSITOL; LIPID METABOLISM; LIPIDS; LONGITUDINAL STUDIES; OBESITY; POLYCYSTIC OVARY SYNDROME; RISK FACTORS; STEREOISOMERISM; TREATMENT OUTCOME;

EID: 84878581057     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. LEGRO RS, BLANCHE P, KRAUSS RM, LOBO RA. Alterations in low-density lipoprotein and high-density lipoprotein subclasses among Hispanic women with polycystic ovary syndrome: influence of insulin and genetic factors. Fertil Steril 1999; 72: 990-995.
2. ELTING MW, KORSEN TJ, SCHOEMAKER J. Obesity, rather than menstrual cycle pattern or follicle cohort size, determines hyperinsulinaemia, dyslipidemia and hypertension in ageing women with polycystic ovary syndrome. Clin Endocrinol 2001; 55: 767-776.
3. DUNAIF A, SEGAL KR, FUTTERWEIT W, DOBRJANSKY A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38: 1165-1174.
4. No authors listed. Polycystic ovary syndrome may raise heart disease risk. Health News 2002; 8: 7.
5. HOLTE J, BERGH T, BERNE C, BERGLUND L, LITHELL H. Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance. J Clin Endocrinol Metab 1994; 78: 1052-1058.
6. LEGRO RS, KUNSELMAN AR, DUNAIF A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 2001; 111: 607-613.
7. RIZZO M, BERNEIS K, HERSBERGER M, PEPE I, DI FEDE G, RINI GB, SPINAS GA, CARMINA E. Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype. Hum Reprod 2009; 24: 2286-2292.
8. DIAMANTI-KANDARAKIS E, PAPAVASSILIOU AG, KANDARAKIS SA, CHROUSOS GP. Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metab 2007; 18: 280-285.
9. DIAMANTI-KANDARAKIS E. Role of obesity and adiposity in polycystic ovary syndrome. Int J Obes (Lond) 2007; 31(Suppl 2): S8-13; discussion S31-12.
10. PIRWANY IR, FLEMING R, GREER IA, PACKARD CJ, SATTAR N. Lipids and lipoprotein sub fractions in women with PCOS: relationship to metabolic and endocrine parameters. Clin Endocrinol 2001; 54: 447-453.
11. WILD RA, PAINTER PC, COULSON PB, CARRUTH KB, RANNEY GB. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1985; 61: 946-951.
12. MORAN L, TEEDE H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod Update 2009; 15: 477-488.
13. MEYER C, MCGRATH BP, CAMERON J, KOTSOPOULOS D, TEEDE HJ. Vascular dysfunction and metabolic parameters in polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90: 4630-4635.
14. ESPINOS-GOMEZ JJ, CORCOY R, CALAF J. Prevalence and predictors of abnormal glucose metabolism in Mediterranean women with polycystic ovary syndrome. Gynecol Endocrinol 2009; 25: 199-204.
15. SAM S, LEGRO RS, ESSAH PA, APRIDONIDZE T, DUNAIF A. Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome. Proc Natl Acad Sci USA2006; 103: 7030-7035.
16. BARR ELM, MAGLIANO DJ, ZIMMET PZ, POLKINGHORNE KR, ATKINS RC, DUNSTAN DW, MURRAY SG, SHAW JE. AusDiab 2005: The Australian Diabetes, Obesity and Lifestyle Study. Melbourne. Second Edition ed. International Diabetes Institute, Melbourne, Australia; 2006.
17. KNOWLER WC, BARRETT-CONNOR E, FOWLER SE, HAMMAN RF, LACHIN JM, WALKER EA, NATHAN DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
18. BARR EL, ZIMMET PZ, WELBORN TA, JOLLEY D, MAGLIANO DJ, DUNSTAN DW, CAMERON AJ, DWYER T, TAYLOR HR, TONKIN AM, WONG TY, MCNEIL J, SHAW JE. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 2007; 116: 151-157.
19. SHAW LJ, BAIREY MERZ CN, AZZIZ R, STANCZYK FZ, SOPKO G, BRAUNSTEIN GD, KELSEY SF, KIP KE, COOPER-DEHOFF RM, JOHNSON BD, VACCARINO V, REIS SE, ET AL. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health-National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008; 93: 1276-1284.
20. No authors listed. Revised 2003 consensus on diagnostic criteria and long-term-health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25.
21. DUNAIF A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18: 774-800.
22. CIBULA D, CIFKOVA R, FANTA M, POLEDNE R, ZIVNY J, SKIBOVA J. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod 2000; 15: 785-789.
23. TALBOTT EO, ZBOROWSKI JV, RAGER JR, BOUDREAUX MY, EDMUNDOWICZ DA, GUZICK DS. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89: 5454-5461.
24. MACUT D, DAMJANOVIC S, PANIDIS D, SPANOS N, GLISIC B, PETAKOV M, ROUSSO D, KOURTIS A, BJEKIC J, MILIC N. Oxidised low-density lipoprotein concentration-early marker of an altered lipid metabolism in young women with PCOS. Eur J Endocrinol 2006; 155: 131-136.
25. WILD S, PIERPOINT T, MCKEIGUE P, JACOBS H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000; 52: 595-600.
26. WILD RA, CARMINA E, DIAMANTI-KANDARAKIS E, DOKRAS A, ESCOBAR-MORREALE HF, FUTTERWEIT W, LOBO R, NORMAN RJ, TALBOTT E, DUMESIC DA. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 2010; 95: 2038-2049.
27. MOSCA L. Guidelines for prevention of cardiovascular disease in women: a summary of recommendations. Prev Cardiol 2007; 10(Suppl 4): 19-25.
28. HUANG LC, FONTELES MC, HOUSTON DB, ZHANG C, LARNER J. Chiroinositol deficiency and insulin resistance. III. Acute glycogenic and hypoglycemic effects of two inositol phosphoglycan insulin mediators in normal and streptozotocin-diabetic rats in vivo. Endocrinology 1993; 132: 652-657.
29. SUN TH, HEIMARK DB, NGUYGEN T, NADLER JL, LARNER J. Both myo-inositol to chiro-inositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls. Biochem Bio-